Prognostic Significance of 18F-FDG PET Parameters and Plasma Epstein-Barr Virus DNA Load in Patients with Nasopharyngeal Carcinoma

The plasma concentration of Epstein-Barr virus (EBV) DNA is associated with tumor burden and prognosis in patients with nasopharyngeal carcinoma (NPC), but data on the relationship between viral load and 18F-FDG PET functional parameters are lacking. We examined the association of 18F-FDG PET functional parameters and EBV DNA load with the clinicopathologic characteristics and clinical outcomes of patients with NPC. Methods: One hundred eight patients with NPC who underwent 18F-FDG PET before treatment were included in this study. We determined total lesion glycolysis (TLG) of the primary tumor, the cervical nodes, and their combination and the maximal standardized uptake value of the primary tumor and cervical lymph nodes. EBV DNA was measured by real-time polymerase chain reaction. Results: EBV DNA was significantly associated with total TLG (R2 = 0.589). Total TLG values had the highest correlation with EBV DNA load and were significantly associated with tumor, nodal, and overall stages. However, tumor TLG greater than the median (>65 g) was the only parameter significantly associated with overall, local recurrence-free, disease-free, and distant metastasis-free survivals (P = 0.033, 0.014, <0.001, and 0.023, respectively). After allowance for potential confounders, tumor TLG retained its independent significance for overall and disease-free survival rates (P = 0.045 and 0.006, respectively). Conclusion: Total TLG values are primarily associated with tumor burden and clinical stage, whereas tumor TLG is the best predictor of patient survival after treatment.

[1]  B. Hamm,et al.  Modification of Aminosilanized Superparamagnetic Nanoparticles: Feasibility of Multimodal Detection Using 3T MRI, Small Animal PET, and Fluorescence Imaging , 2009, Molecular Imaging and Biology.

[2]  S. Leung,et al.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.

[3]  Ukihide Tateishi,et al.  Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. , 2008, Radiology.

[4]  Li‐yu Lee,et al.  Identification of candidate nasopharyngeal carcinoma serum biomarkers by cancer cell secretome and tissue transcriptome analysis: Potential usage of cystatin A for predicting nodal stage and poor prognosis , 2010, Proteomics.

[5]  Ngan-Ming Tsang,et al.  Multiplexed immunobead‐based profiling of cytokine markers for detection of nasopharyngeal carcinoma and prognosis of patient survival , 2011, Head & neck.

[6]  A. Mäkitie,et al.  Correlation of Epstein‐Barr virus DNA in cell‐free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: A pilot study , 2004, Head & neck.

[7]  Y. F. Poon,et al.  Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. , 1992, International journal of radiation oncology, biology, physics.

[8]  John L. Humm,et al.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[9]  T. Yip,et al.  Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling , 2004, Clinical Cancer Research.

[10]  T. Yen,et al.  Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. , 2005, International journal of radiation oncology, biology, physics.

[11]  W. Henle,et al.  Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma , 1976, International journal of cancer.

[12]  Raymond W. M. Ng,et al.  Surgical salvage of persistent or recurrent nasopharyngeal carcinoma with maxillary swing approach — Critical appraisal after 2 decades , 2011, Head & neck.

[13]  Yau-Huei Wei,et al.  Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. , 2004, The New England journal of medicine.

[14]  Kai-Ping Chang,et al.  Salvage Surgery for Locally Recurrent Nasopharyngeal Carcinoma—A 10-Year Experience , 2004, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[15]  P. Johnson,et al.  Serum levels of CYFRA 21-1 in nasopharyngeal carcinoma and its possible role in monitoring of therapy. , 1996, European journal of cancer. Part B, Oral oncology.

[16]  Kai-Ping Chang,et al.  Macrophage Inflammatory Protein-3α Is a Novel Serum Marker for Nasopharyngeal Carcinoma Detection and Prediction of Treatment Outcomes , 2008, Clinical Cancer Research.

[17]  Chen-Yi Hsu,et al.  Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Christopher W. Dawson,et al.  Epstein-Barr virus and nasopharyngeal carcinoma , 2014, Chinese journal of cancer.

[19]  Q. Chan,et al.  Quantitative Assessment of Diffusion-Weighted MR Imaging in Patients with Primary Rectal Cancer: Correlation with FDG-PET/CT , 2010, Molecular Imaging and Biology.

[20]  Kai-Ping Chang,et al.  The 30‐bp Deletion of Epstein‐Barr Virus Latent Membrane Protein‐1 Gene Has No Effect in Nasopharyngeal Carcinoma , 2006, The Laryngoscope.

[21]  U. Prasad,et al.  Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. , 1999, International Journal of Cancer.

[22]  T. Mok,et al.  Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Y. Shih,et al.  Plasma Epstein‐Barr virus DNA screening followed by 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma , 2011, Cancer.

[24]  Z. Fu,et al.  Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  T. Yen,et al.  [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Yen,et al.  Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  S. Larson,et al.  Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. , 2004, Journal of the American College of Surgeons.

[28]  Chun-Ta Liao,et al.  Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  T. Yen,et al.  Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Kai-Ping Chang,et al.  Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma. , 2008, Oral oncology.

[31]  J. Epstein,et al.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. , 1991, The American journal of pathology.

[32]  T. Yen,et al.  Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. , 2009, Oral oncology.

[33]  M. Choti,et al.  Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy , 2007, Journal of Gastrointestinal Surgery.

[34]  S. H. Cheng,et al.  Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. , 2000, International journal of radiation oncology, biology, physics.

[35]  Brian O'Sullivan,et al.  New TNM staging criteria for head and neck tumors. , 2003, Seminars in surgical oncology.

[36]  E. Hui,et al.  Plasma Osteopontin, Hypoxia, and Response to Radiotherapy in Nasopharyngeal Cancer , 2008, Clinical Cancer Research.

[37]  S. T. Liu,et al.  Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification , 1990, Journal of clinical microbiology.

[38]  S. Leung,et al.  Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Ching-Han Hsu,et al.  Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes? , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  C. Sam,et al.  Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-β1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma , 2006, BMC Cancer.

[41]  U. Prasad,et al.  Elevated serum levels of transforming growth factor β1 in Epstein‐Barr virus‐associated nasopharyngeal carcinoma patients , 1999 .

[42]  John L. Humm,et al.  Use of PET to monitor the response of lung cancer to radiation treatment , 2000, European Journal of Nuclear Medicine.

[43]  W. Wei,et al.  Efficacy of radical neck dissection for the control of cervical metastasis after radiotherapy for nasopharyngeal carcinoma. , 1990, American journal of surgery.

[44]  A. King,et al.  Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. , 2006, International journal of radiation oncology, biology, physics.